Tolterodine Fumarate

DUBLIN--( BUSINESS WIRE )--The "Overactive Bladder Treatment (OAB) Market by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) and Region - Global Forecasts to 2027" report has been added to ResearchAndMarkets.com's offering. The global overactive bladder treatment market is projected to reach USD 4.2 billion by 2027 from USD 3.5 billion in 2022, at a CAGR of 3.6% Rising prevalence of overactive bladder across the globe coupled with rising awareness about treatment options available is driving the growth of the market. Additionally, use of neuromodulation techniques for the treatment of OAB is further expected to have a significant positive impact. The adoption of novel treatments and the launch of new drugs for OAB treatment are also likely to support market growth in the coming years. Mirabegron segment dominates the overactive bladder (OAB) treatment market in 2021. Based on type, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments. Mirabegron held a dominant share of the market in 2021, owing to the lesser side-effects associated with this drug compared to other drug classes available in the market. Furthermore, neuromodulation segment is expected to grow at faster pace owing to launch of new SNM & PTNS for OAB in market. The idiopathic overactive bladder segment will witness the highest growth in overactive bladder treatment market during the forecast period. Based on disease type, the overactive bladder treatment market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. The idiopathic overactive bladder segment accounted for a larger market share due to the higher prevalence of idiopathic overactive bladder disorders and increased use of drugs for the treatment. North America held dominant share in 2021. In 2021, North America accounted for the major share in the OAB treatment market. North America holds majority of the key market players leading to maturity of OAB treatment market in this region. Furthermore, favorable reimbursement policies in US is one of the leading factor projecting market growth in North America. Competitive landscape The prominent players in this market are Astellas Pharma Inc. (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer Inc. (US), Medtronic Plc (Ireland), AbbVie Inc. (US), Viatris Inc. (US), Hisamitsu Pharmaceutical Co., Inc. (Japan), Johnson & Johnson Services, Inc. (US), and Endo Pharmaceuticals Inc. (Ireland). Market Dynamics Market Drivers Rising Prevalence of Overactive Bladder Syndrome Rapidly Aging Population and Subsequent Rise in Incidence of Diseases Characterized by Oab Development and Use of Innovative Intravesical Therapies Growing R&D Investments and the Launch of Novel Therapies in the Coming Years Market Restraints Frequent Product Recalls Increased Side-Effects of Anticholinergic Drugs Market Opportunities Novel Treatments, Robust Pipelines, and Patent Cliff of Certain Drugs Market Challenges Social Stigma and Lack of Awareness About OAB Companies mentioned: Abbvie Inc Ajanta Pharma Altherx Pharmaceuticals Amneal Pharmaceuticals LLC Apotex Inc Astellas Pharma Inc Bayer Ag Endo Pharmaceuticals Inc Glenmark Granules India Limited Hisamitsu Pharmaceutical Co Inc Hugel, Inc Intas Pharmaceuticals Ltd Johnson & Johnson Services, Inc Laborie Lupin Macleods Pharmaceuticals Ltd Medtronic Medytox Pfizer Inc Sun Pharmaceutical Industries Ltd Taiho Pharmaceutical Co Ltd Teva Pharmaceutical Industries Ltd Urovant Sciences Viatris Inc For more information about this report visit https://www.researchandmarkets.com/r/2n1a4y About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Urovant Sciences, the former subsidiary of Vivek Ramaswamy’s Roivant Sciences, is branching out across the Atlantic in a new licensing deal. The California biotech and French multinational pharma and cosmetics company Pierre Fabre jointly announced Tuesday that they are pairing up, with Urovant giving Pierre Fabre the rights to register and commercialize overactive bladder drug vibegron, known as Gemtesa in several markets, including the entire EU, Iceland, Liechtenstein, Norway, the UK and Switzerland. The deal also includes a few option territories which, according to a statement, include “French-speaking countries of Sub-Saharan Africa, Turkey and certain Eastern European countries.” Urovant will retain full rights in the US and other unnamed markets, according to the statement. As part of the deal, Urovant will also receive up to $75 million in combined upfront payments plus regulatory and sales milestones, and topping that off with potential royalties. Urovant CEO Jim Robinson expressed excitement at the deal, adding that the French pharma’s “experience in the global OAB and Benign Prostatic Hyperplasia (BPH) market make them uniquely suited to deliver vibegron to more patients.” The pair will also be working together on conducting pediatric trials in Europe for the drug, which was bagged by Ramaswamy from Merck for $25 million. Urovant will also be “providing manufacturing services” to Pierre Fabre. Gemtesa originally hit the market in late 2020 after the FDA gave it the green light. The former Ramaswamy outfit, which was sold to a Sumitomo Dainippon subsidiary for $584 million in an all-cash deal, had previously laid out a positive Phase III readout, showing that the drug candidate had hit its co-primary endpoints and seven secondary endpoints compared to placebo after three months of treatment and a one-month safety follow-up. However, Urovant had tested the drug alongside tolterodine, a cheap generic that also achieved statistical significance over placebo. Researchers said at the time that even though Gemtesa achieved “numerically better efficacy than tolterodine,” they did not run a p-value outlining the statistical significance of the treatment effect. After that saga, the drug then passed a safety study in September, showing that it had no clinically relevant effect on blood pressure and heart rate. Endpoints News has reached out to Urovant and will update accordingly.